- Home
- BSBR vs ONC Comparison
BSBR vs ONC Comparison
Compare BSBR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBR | ONC |
|---|---|---|
| Founded | 1970 | 2010 |
| Country | Brazil | Switzerland |
| Employees | N/A | 12000 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 31.4B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | BSBR | ONC |
|---|---|---|
| Price | $5.30 | $325.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $385.10 |
| AVG Volume (30 Days) | ★ 1.7M | 359.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.04 | $723.76 |
| Revenue Next Year | $6.59 | $15.04 |
| P/E Ratio | ★ $11.02 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $253.95 |
| 52 Week High | $7.32 | $385.22 |
Technical Indicators
Market Signals| Indicator | BSBR | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 70.68 |
| Support Level | $5.21 | $325.47 |
| Resistance Level | $5.55 | $328.39 |
| Average True Range (ATR) | 0.12 | 8.01 |
| MACD | 0.02 | 2.16 |
| Stochastic Oscillator | 66.60 | 88.46 |
Price Performance
Historical ComparisonAbout BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.